(Reuters) – Merck, along with its partner Moderna, began a late-stage study to evaluate their experimental mRNA-based cancer vaccine in combination with cancer therapy Keytruda, the companies said on Wednesday.
(Reporting by Bhanvi Satija in Bengaluru; Editing by Shilpi Majumdar)
